To include your compound in the COVID-19 Resource Center, submit it here.

Follow-on roundup: Horizon, Apellis, Epizyme

Horizon, Apellis and Epizyme each priced follow-ons raising a total of $552 million.

Horizon Pharma plc (NASDAQ:HZNP) raised $300 million late Wednesday through the sale of 12 million shares at $24.50. The price is a

Read the full 342 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE